Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
Guy Levy Insider Alerts

Get notified the next time Guy Levy buys or sells BioAtla stock. Enter your email address below to get our daily insider buying and selling report.

Guy Levy Insider Information

Director of BioAtla


Guy Levy is the founder and Managing Member of Soleus Capital Management, L.P. ("Soleus"). His career spans 18 years in healthcare and life sciences. Prior to founding Soleus, Guy worked at Paulson & Co. where he was most recently a partner and portfolio manager. Prior to that, Guy worked as an investment analyst at Shumway Capital and Warburg Pincus. Guy began his career at Morgan Stanley, where he worked in the mergers & acquisitions and healthcare investment banking divisions. Guy holds a B.A. from Yale University, where he graduated summa cum laude.

How do I contact Guy Levy?

The corporate mailing address for Mr. Levy and other BioAtla executives is , , . BioAtla can also be reached via phone at 858-558-0708 and via email at [email protected]

Has Guy Levy been buying or selling shares of BioAtla?

Guy Levy has not been actively trading shares of BioAtla within the last three months. Most recently, Guy Levy sold 546,709 shares of the business's stock in a transaction on Tuesday, August 24th. The shares were sold at an average price of $39.65, for a transaction totalling $21,677,011.85.

Who are BioAtla's active insiders?

BioAtla's insider roster includes Guy Levy (Director), Jay Short (CEO), Eric Sievers (Insider), Scott Smith (President), and Lawrence Steinman (Director).

Are insiders buying or selling shares of BioAtla?

During the last year, BioAtla insiders bought shares 2 times. They purchased a total of 2,188,890 shares worth more than $39,400,020.00. During the last year, insiders at the sold shares 21 times. They sold a total of 1,113,621 shares worth more than $43,306,122.45. The most recent insider tranaction occured on November, 24th when CFO Richard A Waldron sold 3,937 shares worth more than $97,913.19. Insiders at BioAtla own 35.5 % of the company.

Information on this page was last updated on 11/24/2021.

Guy Levy Insider Trading History at BioAtla

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/24/2021Sell546,709$39.65$21,677,011.85View SEC Filing Icon  
12/18/2020Buy1,388,890$18.00$25,000,020.00View SEC Filing Icon  
See Full Table

Guy Levy Buying and Selling Activity at BioAtla

This chart shows Guy Levy's buying and selling at BioAtla by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioAtla Company Overview

BioAtla logo
BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.
Read More

Today's Range

Now: $22.50
Low: $21.55
High: $23.40

50 Day Range

MA: $27.89
Low: $21.80
High: $31.80

2 Week Range

Now: $22.50
Low: $21.38
High: $76.63

Volume

821,483 shs

Average Volume

180,357 shs

Market Capitalization

$828.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!